Cargando…

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19

Detalles Bibliográficos
Autores principales:	Dutt, Tina, Simcox, David, Downey, Colin, McLenaghan, Daniella, King, Charlotte, Gautam, Manish, Lane, Steven, Burhan, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737584/ https://www.ncbi.nlm.nih.gov/pubmed/32931711 http://dx.doi.org/10.1164/rccm.202007-2913LE

Ejemplares similares

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Growth kinetics of Salmonella enterica in Hajna tetrathionate broth, Rappaport broth and modified semisolid Rappaport agar
por: FUJIHARA, Masatoshi, et al.
Publicado: (2015)

An Integrated Approach to the Exposome: Rappaport and Lioy Respond
por: Rappaport, Stephen M., et al.
Publicado: (2012)

Simultaneous Salmonella and bacteriophage isolation on Modified Semisolid Rappaport Vassiliadis media
por: Torres-Boncompte, Jan, et al.
Publicado: (2023)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Rappaport Furrows on Our Minds: The ASCB Cytokinesis Meeting Burlington, VT July 22–25, 2004
por: Canman, Julie C., et al.
Publicado: (2004)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Draft Genome Sequence of a New Bacterium Named Rappaport israeli, gen. nov., sp. nov., Isolated from a Blood Culture
por: Waldman Ben-Asher, Hiba, et al.
Publicado: (2017)

Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism
por: Haider, Zahra, et al.
Publicado: (2021)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

Pneumococcal colonisation is an asymptomatic event in healthy adults using an experimental human colonisation model
por: Trimble, Ashleigh, et al.
Publicado: (2020)

Thirteen-Valent Pneumococcal Conjugate Vaccine–Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung
por: Mitsi, Elena, et al.
Publicado: (2021)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study
por: Andersen, Kathleen M., et al.
Publicado: (2022)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2019)

Deep vein thrombosis and thromboprophylaxis in arthroscopic anterior cruciate ligament reconstruction
por: Adala, Raviraj, et al.
Publicado: (2011)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
por: Farkh, Carine, et al.
Publicado: (2021)

Computer methods in general relativity: algebraic computing
por: Araujo, M E, et al.
Publicado: (1992)

Reply to Turnbull et al. and to Hulme et al.
por: Breuer, Oded, et al.
Publicado: (2020)

Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition
por: Han, Han, et al.
Publicado: (2021)

Green by Design: Convergent Synthesis, Computational Analyses, and Activity Evaluation of New FXa Inhibitors Bearing Peptide Triazole Linking Units
por: Rodríguez, Diego F., et al.
Publicado: (2021)

Obstetric Thromboprophylaxis: The Swedish Guidelines
por: Lindqvist, Pelle G., et al.
Publicado: (2011)

Pharmacological thromboprophylaxis and epidural anaesthesia
por: Harsoor, SS, et al.
Publicado: (2012)

Thromboprophylaxis in routine arthroscopy of knee
por: Abouali, Jihad, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sg5vbrio218f44sfcbut1kntv4